H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
15%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Get your full text copy in PDF

Oral citicoline treatment improves visual pathway function in glaucoma.

Robert Rejdak, Jerzy Toczołowski, Jacek Kurkowski, Marek Kamiński, Konrad Rejdak, Zbigniew Stelmasiak, Paweł Grieb

Med Sci Monit 2003; 9(3): PI24-28

ID: 4717


BACKGROUND: Increased latency and reduced amplitude of visual evoked potentials (VEP), frequently encountered in ocular hypertension or open-angle glaucoma, suggest slowed neural conduction in the visual pathways. An improvement in VEP latency and amplitude has been reported following repeated intramuscular injections of citicoline, a neuroprotective drug. Our aim was to find whether citicoline given orally would produce a similar effect. MATERIAL/METHODS: VEP latency and amplitude were measured in 21 glaucomatous eyes prior to and after two bi-weekly courses of citicoline taken orally in a dose of 1 gram/day. The treatment courses were separated by a two-week break; post-treatment VEP measurement was performed two weeks after the end of the second treatment. RESULTS: 62% of the eyes showed a response to the treatment, with VEP latency reduced from 123.5 (3.9 SEM) ms to 111.9 (1.9 SEM) ms (P=0.0008), and VEP amplitude increased from 6.56 (1.39 SEM) to 7.88 (1.16 SEM) (P=0.04). CONCLUSIONS: Citicoline given orally improves visual evoked potentials in some glaucoma patients.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree